在轻链淀粉样变性中，反应至关重要，不惜一切代价。

Response matters in light chain amyloidosis, whatever it takes.

机构信息

Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy.

出版信息

Br J Haematol. 2024 Jul;205(1):25-27. doi: 10.1111/bjh.19581. Epub 2024 Jun 6.

DOI:10.1111/bjh.19581

PMID:38842142

Abstract

Access to upfront daratumumab for AL amyloidosis is expanding, but it is not universal. Bomsztyk et al. show that patients who do not receive front-line daratumumab can be effectively rescued with this agent, indicating that deep haematological response should be pursued tenaciously. Commentary on: Bomsztyk et al. Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain (AL) amyloidosis after initial bortezomib-based regime. Br J Haematol 2024;205:138-145.

摘要

upfront daratumumab 用于淀粉样变的可及性正在扩大，但并非普及。Bomsztyk 等人的研究表明，未接受一线 daratumumab 治疗的患者可以用该药有效挽救，表明应坚决追求深度血液学缓解。述评：Bomsztyk 等人。在初始硼替佐米为基础的方案后复发/难治性轻链（AL）淀粉样变性患者中，二线用 daratumumab 硼替佐米地塞米松（DVD）治疗的反应率。Br J Haematol 2024;205:138-145。